For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca PLC closed 17.61% short of its 52-week high of £133.88, which the company reached on September 3rd.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Russian drugmaker Axelpharm has managed to lift the ban on the launch of osimertinib - a drug, which is used in the treatment ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55 ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Astrazeneca unveiled overhaul of its manufacturing and supply operations driven by deep tech and AI at London Tech Week.

AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...